Tech
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Publication: Ars Technica - All content
Author: Beth Mole
Source published: 29/09/2026, 22:30:37 UTC
Briefing created: 01/10/2026, 07:02:56 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 30/09/2026, 18:43:25 UTC.
Briefings
A late-stage clinical trial for retatrutide, a new obesity drug, reported significant weight loss results. Participants on the highest dose lost an average of 25% of body weight after 80 weeks and 30% after 104 weeks. The trial began in 2023 with 2,339 participants from 131 sites across 11 countries. Results were published in the New England Journal of Medicine.
Key points
- Participants on the highest retatrutide dose lost an average of 25 percent of their body weight after 80 weeks of treatment.
- The trial included 2,339 participants from 131 clinical trial sites in 11 countries, with 574 having knee osteoarthritis and 243 having obstructive sleep apnea.
Context and limitations
Data covers only the 80-week and 104-week periods; initial prediabetes resolution rates are reported but not broken down by specific subgroups.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 01/10/2026, 07:02:56 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiaeiubpmtdls2lzzhxicroguwapfnb2hkgae77htoteuovjnhegjy